RxDoctor Payments Data

John Still, MD

Family Medicine · Greenville, NCNPI 1689203796

Payments from drug & device makers

$2,742in general payments, 2019–2025

Across 111 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$801
  • Novo Nordisk$437
  • AbbVie$272
  • Amgen$218
  • Lilly USA, LLC$184
  • Boehringer Ingelheim$129
  • plus $700 from 14 others

What the payments were for

  • Food & beverage$2,742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,742 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$85,911
Medicare patients
202
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$60,087
EliquisApixaban53$47,606
JardianceEmpagliflozin45$37,307
MounjaroTirzepatide25$33,453
TrulicityDulaglutide15$16,092
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,702
VascepaIcosapent Ethyl13$7,515
SynthroidLevothyroxine Sodium42$4,272
Testosterone Cypionate37$3,780
Novolog FlexpenInsulin Aspart14$3,592
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,643
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,279
Rosuvastatin Calcium165$2,004
Levothyroxine Sodium165$1,906
Atorvastatin Calcium172$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$437$60,08744 claims
Lilly USA, LLCMounjaro, Trulicity$184$49,54540 claims
PfizerEliquis$111$47,60653 claims
Boehringer IngelheimJardiance$129$37,30745 claims
AstraZenecaBreztri Aerosphere$801$8,70214 claims
AbbVieSynthroid$272$4,27242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →